🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Omada Health, Inc. OMDA R2K

Healthcare · Health Information Services · United States
https://www.omadahealth.com

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.

READ MORE ›
$17.97
-21.87% 1Y

Market & Price

Market Cap
$1.07B
Current Price
$17.97
High / Low (52W)
$26.78 / $10.94
Beta
-

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
37.71
PEG Ratio
-
Book Value
$3.95
Price to Book
4.55
P/S
3.77
EV/EBITDA
-318.29
Dividend Yield
-

Profitability & Returns

ROCE
-4.46%
ROE
-4.30%
ROA
-2.35%
Profit Margin
-2.22%
Op Margin
-6.13%
EPS (Latest Qtr)
$-0.05
EPS (TTM)
$-0.23

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
3.69
Current Ratio
3.92
Debt
$0
Total Assets
$305.41M
Current Assets
$272.93M
Working Capital
$197.21M

Ownership

Promoter Holding
2.19%
Chg in Prom Hold
-
FII / Inst Holding
81.61%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$856.52M
Total Revenue (TTM)
$283.30M
EBITDA
$-2.69M
Free Cash Flow
$16.81M
Operating Cash Flow
$22.54M
Shares Outstanding
59.45M
Gross Margin
66.27%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
42.89%
Profit 5Y
27.46%
Revenue (YoY)
42.00%
Earnings (YoY)
-

PROS

  • Compounding revenue at 42.9% over 5 years.
  • Profit CAGR of 27.5% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 32.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 OMDA Omada Health, Inc. R2K 17.97 - $1.07B - -4.46% -4.30% 42.89% 27.46%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -41.21M45.52M54.96M61.37M68.03M75.85M78.05M
Cost of Revenue ---23.06M21.07M22.96M22.18M29.36M
Gross Profit -24.83M28.56M31.90M40.31M45.07M53.66M48.69M
Operating Expenses ---40.30M44.65M47.58M50.38M53.47M
Operating Income --10.04M-8.52M-8.40M-4.34M-2.51M3.28M-4.78M
EBITDA ----7.04M-2.87M-1.47M6.62M-1.44M
Interest Expense ---1.07M1.09M353.00K13.00K18.00K
Pretax Income ----9.45M-5.31M-3.18M5.16M-2.97M
Tax Provision ---00000
Net Income -18.97M-10.69M-9.23M-9.45M-5.31M-3.18M5.16M-2.97M
Diluted EPS --1.40-1.18-0.17-0.24-0.060.08-0.05
R&D Expense -8.99M8.85M8.81M10.02M10.30M-12.70M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 89.19M122.78M169.80M260.21M
Cost of Revenue 46.39M52.81M66.92M89.27M
Gross Profit 42.79M69.97M102.88M170.94M
Operating Expenses 115.14M135.97M146.53M182.91M
Operating Income -72.35M-66.00M-43.65M-11.97M
EBITDA -63.99M-58.36M-37.83M-4.75M
Interest Expense 4.20M4.71M4.51M2.53M
Pretax Income -72.52M-67.51M-47.14M-12.78M
Tax Provision 0000
Net Income -72.52M-67.51M-47.14M-12.78M
Diluted EPS -1.52-1.41-0.85-0.35
R&D Expense -33.74M35.92M40.68M

Compounded Sales Growth

5 Years:42.89%
1 Year:42.00%

Compounded Profit Growth

5 Years:27.46%
1 Year:-

Stock Price Performance

1 Year:-21.87%
6 Months:-0.88%
3 Months:+46.34%
1 Month:+27.00%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets 221.80M175.08M150.89M305.41M
Current Assets 188.56M142.88M113.06M272.93M
Cash & Equivalents 168.12M115.64M76.39M222.04M
Inventory 3.54M3.61M3.30M4.49M
Receivables 4.93M7.58M9.48M13.56M
Total Liabilities 66.19M76.16M535.29M75.73M
Current Liabilities 34.51M43.79M53.95M75.73M
Long Term Debt 28.89M29.38M29.77M-
Total Debt 30.81M30.58M30.19M0
Total Equity 155.60M98.92M-384.40M229.68M
Shares Outstanding 55.74M55.74M55.74M58.43M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -68.98M-49.74M-34.18M18.25M
Investing Cash Flow -2.72M-2.92M-3.86M-5.83M
Financing Cash Flow 16.32M179.00K-1.21M133.22M
Capital Expenditure -2.72M-2.92M-3.86M-5.83M
Free Cash Flow -71.70M-52.66M-38.04M12.42M
Net Change in Cash -55.38M-52.48M-39.25M145.64M

Ratios (Annual)

Figures in %.

Metric Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 48.0%57.0%60.6%65.7%
Operating Margin % -81.1%-53.8%-25.7%-4.6%
Net Margin % -81.3%-55.0%-27.8%-4.9%
ROE % -46.6%-68.2%12.3%-5.6%
ROCE % -38.6%-50.3%-45.0%-5.2%

Shareholding Pattern

Insiders
2.19%
Institutions
81.61%
Public Float
83.44%

Top Institutional Holders

#Holder% HeldSharesValue
1 Divisadero Street Capital Management, LP 9.90% 5.89M $105.80M
2 Revelation Capital Management, LLC 8.76% 5.21M $93.59M
3 Cigna Investments Inc/New 5.79% 3.44M $61.90M
4 FMR, LLC 5.53% 3.29M $59.09M
5 NVP Associates, LLC 4.26% 2.53M $45.48M
6 American Century Companies Inc 4.13% 2.46M $44.14M
7 a16z Capital Management, L.L.C. 3.88% 2.31M $41.46M
8 Blackrock Inc. 3.20% 1.90M $34.22M
9 Vanguard Capital Management LLC 3.04% 1.81M $32.51M
10 LOOMIS SAYLES & CO L P 2.88% 1.71M $30.78M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for OMDA

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space